Rheumatoid arthritis (RA) is a chronic systemic autoimmune disease characterised by synovial joint inflammation leading to cartilage destruction and bone erosion. Early diagnosis and treatment is essential to minimise the risk of future joint damage and disability. Treatment options include conventional disease-modifying anti-rheumatic drugs (DMARDS) such as methotrexate, and biological therapies including tumour necrosis factor (TNF) inhibitors and interleukin-6 antagonists. However, some patients fail to respond to biologic therapies. An exciting new development is small molecule DMARDs targeting intracellular signalling pathways, which include Janus kinase (JAK) inhibitors. Other recent developments include a biologic DMARD that targets and suppresses the inflammatory cytokine granulocyte-macrophage colony-stimulating factor (GM-CSF).
Expert video highlights and insights from the conference hub and comprehensive peer-reviewed articles from our journal portfolio provide updates on the changing treatment landscape. To learn more about how the latest developments impact on patient outcomes view our expert-led learning activities.
Rheumatoid Arthritis Content
Kevin Winthrop, ACR 2022: Integrated safety analysis of filgotinib in moderately to severely active rheumatoid arthritis
Filgotinib, is an oral Janus kinase 1 inhibitor approved in Europe, Japan, and the UK for the treatment of patients with moderately to severely active rheumatoid arthritis (RA). In this touchIMMUNOLOGY interview, we caught up with Prof. Kevin Winthrop (Oregon Health & Science University, Portland, OR, USA) to discuss the objectives, methodology and findings from […]
Paul Studenic, ACR 2022: A validation study of the revised ACR/EULAR remission criteria for rheumatoid arthritis
ACR and EULAR endorsed provisional criteria, both Boolean and index-based, to define remission in rheumatoid arthritis over 10 years ago, in 2022 a revision of the remission criteria has been made. touchIMMUNOLOGY were delighted to speak with Dr. Paul Studenic (Medical University of Vienna, Vienna, Austria) to discuss the methodology and findings of the validation […]
Paul Studenic, ACR 2022: The 2022 revision of the ACR/EULAR remission criteria for rheumatoid arthritis
ACR and EULAR endorsed provisional criteria, both Boolean and index-based, to define remission in rheumatoid arthritis (RA) over 10 years ago, in 2022 a revision of the remission criteria has been made. touchIMMUNOLOGY were delighted to speak with Dr. Paul Studenic (Medical University of Vienna, Vienna, Austria) to discuss the limitations of the Boolean and […]
Kim Lauper, ACR 2022: Safety of JAK-inhibitors in rheumatoid arthritis in a real-world population
The JAK inhibitor (JAKi) tofacitinib was associated with an increased risk of serious adverse events compared to TNF-inhibitors in the treatment of rheumatoid arthritis in the ORAL surveillance study (NCT02092467). In this interview, touchIMMUNOLOGY were delighted to speak with Dr. Kim Lauper (Geneva University Hospitals, Genéve, Switzerland) around her study assessing the safety of JAKis […]
Janet Pope, ACR 2022: Patient adherence to therapy in rheumatoid arthritis – the Canadian early arthritis cohort study
The Canadian Early Arthritis Cohort Study, was a real-world patient study looking at adherence to early DMARD strategies in newly diagnosed rheumatoid arthritis (RA) patients seen in routine care. In this touchIMMUNOLOGY interview, it was a pleasure to talk with Dr. Janet Pope (University of Western Ontario, London, ON, Canada) to discuss the importance of patient […]
Siri Lillegraven, ACR 2022: Drug free remission in rheumatoid arthritis – findings from ARCTIC REWIND
The ARCTIC REWIND project (NCT01881308) was a phase 4 study that investigated the withdrawal of disease-modifying antirheumatic drugs in rheumatoid arthritis (RA). In this touchIMMUNOLOGY interview, we were delighted to speak to Dr. Siri Lillegraven (Diakonhjemmet Hospital, Oslo, Norway) to discuss how achievable drug free remission is as a treatment goal in RA, an overview […]
Patrick Durez, ACR 2022: Adverse event reporting in rheumatoid arthritis clinical trials – an analysis of long-term filgotinib integrated safety data
Different methods such as exposure-adjusted incidence rates and exposure-adjusted event rates are used to report adverse events in rheumatoid arthritis (RA) clinical trials, this study compared different methodologies of reporting in long-term filgotinib integrated safety data. touchIMMUNOLOGY were delighted to speak with Prof Patrick Durez (Cliniques Universitaires Saint-Luc – Université Catholique de Louvain (UCL), Brussels, […]
Vibeke Strand, ACR 2022: Analysis of patient reported outcomes from CREDO 2 and CREDO 3 studies of olokizumab
CREDO 2 (NCT02760407) and CREDO 3 (NCT02760433) were phase 3 randomised controlled trials, that investigated the efficacy and safety of olokizumab compared to placebo and adalimumab in moderate to severely active rheumatoid arthritis (RA). touchIMMUNOLOGY were delighted to speak with Prof. Vibeke Strand (Stanford University, Palo Alto, CA, USA) to discuss the findings from her […]
Alan J. Kivitz, ACR 2022: A phase 2 trial of dazodalibep in rheumatoid arthritis
Dazodalibep is a CD40 ligand antagonist recently investigated in a phase 2 double-blind trial for the treatment of active moderate-severe rheumatoid arthritis (RA) with inadequate response to disease-modifying anti-rheumatic drugs (NCT04163991). We were delighted to speak to Dr. Alan J. Kivitz (Altoona Center for Clinical Research, Duncansville, PA, USA) to discuss the rationale for investigating […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!